Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis

W. T. Hughes, V. L. Gray, W. E. Gutteridge, V. S. Latter, M. Pudney

Research output: Contribution to journalArticle

Abstract

The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of ≥ 100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90% or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinii pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50% of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50% of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprim-sulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 μg or more of 556C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.

Original languageEnglish (US)
Pages (from-to)225-228
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume34
Issue number2
StatePublished - 1990
Externally publishedYes

Fingerprint

Atovaquone
Pneumocystis carinii
Pneumonia
Sulfamethoxazole Drug Combination Trimethoprim
Pharmaceutical Preparations
Immunosuppression
Therapeutics
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Hughes, W. T., Gray, V. L., Gutteridge, W. E., Latter, V. S., & Pudney, M. (1990). Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrobial Agents and Chemotherapy, 34(2), 225-228.

Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. / Hughes, W. T.; Gray, V. L.; Gutteridge, W. E.; Latter, V. S.; Pudney, M.

In: Antimicrobial Agents and Chemotherapy, Vol. 34, No. 2, 1990, p. 225-228.

Research output: Contribution to journalArticle

Hughes, WT, Gray, VL, Gutteridge, WE, Latter, VS & Pudney, M 1990, 'Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis', Antimicrobial Agents and Chemotherapy, vol. 34, no. 2, pp. 225-228.
Hughes, W. T. ; Gray, V. L. ; Gutteridge, W. E. ; Latter, V. S. ; Pudney, M. / Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. In: Antimicrobial Agents and Chemotherapy. 1990 ; Vol. 34, No. 2. pp. 225-228.
@article{87f14739a81f4b8280398f05fa8eba25,
title = "Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis",
abstract = "The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of ≥ 100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90{\%} or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinii pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50{\%} of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50{\%} of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprim-sulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 μg or more of 556C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.",
author = "Hughes, {W. T.} and Gray, {V. L.} and Gutteridge, {W. E.} and Latter, {V. S.} and M. Pudney",
year = "1990",
language = "English (US)",
volume = "34",
pages = "225--228",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis

AU - Hughes, W. T.

AU - Gray, V. L.

AU - Gutteridge, W. E.

AU - Latter, V. S.

AU - Pudney, M.

PY - 1990

Y1 - 1990

N2 - The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of ≥ 100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90% or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinii pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50% of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50% of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprim-sulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 μg or more of 556C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.

AB - The efficacy of a new class of drugs for Pneumocystis carinii pneumonitis was demonstrated. 566C80, a hydroxynaphthoquinone, administered orally in a dose of ≥ 100 mg/kg of body weight per day prophylactically prevented P. carinii pneumonitis in 90% or more of rats, while all untreated control animals developed pneumonitis. When 566C80 (100 mg/kg per day) was administered for 3 weeks after P. carinii pneumonitis was established, therapy was totally effective and all of the untreated controls had progressive P. carinii pneumonitis. A dose of 566C80 of between 25 and 50 mg/kg per day protected 50% of the rats from P. carinii pneumonitis, and a dose of between 50 and 100 mg/kg per day cured 50% of those treated for P. carinii pneumonitis. Both prophylaxis and treatment with 566C80 were at least as effective as with trimethoprim-sulfamethoxazole. Animals maintained on immunosuppression after completion of treatment remained free of P. carinii, suggesting a killing effect. Clearance of P. carinii was associated with levels of 60 μg or more of 556C80 per ml of plasma. This hydroxynaphthoquinone offers promise as an anti-P. carinii drug.

UR - http://www.scopus.com/inward/record.url?scp=0025037605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025037605&partnerID=8YFLogxK

M3 - Article

C2 - 2327770

AN - SCOPUS:0025037605

VL - 34

SP - 225

EP - 228

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -